Adjuvant Trastuzumab Effect on HER2-Positive Breast Cancers According to Hormonal Receptor (HR) Status: Crosstalk between ER and EGFR/HER2 Pathway May Prevent Trastuzumab from Improving Outcomes in HER2-Positive and HR-Positive Breast Cancers

被引：0
|
作者：
Park, Y. H. [1 ]
Choi, E. Y. [1 ]
Lee, J. E. [1 ]
Nam, S. J. [1 ]
Yang, J. H. [1 ]
Ahn, J. S. [1 ]
Im, Y-H [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-12-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-12-15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [2] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
  • [3] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [4] Optimizing treatment for HER2-positive HR-positive breast cancer
    Debien, Veronique
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    CANCER TREATMENT REVIEWS, 2023, 115
  • [5] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [6] Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?
    Kim, Jisun
    Pareja, Fresia
    Weigelt, Britta
    Reis-Filho, Jorge S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
  • [7] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [8] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [9] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [10] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
12345